In continuation to its earlier communication dated May 9, 2025 regarding the USFDA inspection, SMS Lifesciences India has informed that the Company has received Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the U.S. Food and Drug Administration for its API manufacturing facility (Unit 1) located at Kazipally, Telangana, on July 15, 2025 at 09.37 pm. The receipt of EIR reaffirms the Company’s commitment to maintaining global quality standards and enables access to the regulated US market and other highly regulated global markets.
The above information is a part of company’s filings submitted to BSE.
